Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma
International Journal of Molecular Sciences · 24.07.2026 · 27 (15) · 6602
DOI: 10.3390/ijms27156602 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.07.2026. Verfasst von Songze Leng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. Hauptthemen laut MEDLINE: Adenosine Deaminase, Multiple Myeloma, RNA-Binding Proteins, Signal Transduction. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hei-longjiang Province, a transvers research project funded by the Bei jing Huikang Charity Foundation, Beijing Huikang Charity Foundation.
Abstract (Originalsprache)
Multiple myeloma (MM) remains an incurable hematological malignancy in which tumor-intrinsic immune evasion limits the efficacy of immunotherapy. Here, we identify the RNA editing enzyme ADAR1 as a key regulator of innate immune suppression in MM. Integrative analyses of bulk and single-cell transcriptomic datasets, together with clinical validation, demonstrated that ADAR1 is upregulated in malignant plasma cells and is associated with adverse clinical outcomes and reduced CD8+ T-cell infiltration. Mechanistically, ADAR1 knockdown increased the association of endogenous dsRNA with melanoma differentiation-associated protein 5 (MDA5), restoring type I interferon (IFN) signaling, enhancing IFNα production and STAT1 activation, and promoting CD8+ T-cell proliferation and cytotoxic function. These effects were largely abolished by MDA5 depletion, establishing a functional ADAR1–MDA5 signaling axis in MM. In vivo, treatment with 8-azaadenosine significantly potentiated the antitumor efficacy of PD-1 blockade, resulting in reduced tumor growth, increased tumor cell apoptosis, elevated IFNα expression, and enhanced CD8+ T-cell infiltration. Together, our findings demonstrate that ADAR1-mediated RNA editing enables immune evasion by restricting MDA5-dependent sensing of endogenous dsRNA and highlight the ADAR1–MDA5-type I interferon axis as a promising therapeutic target for improving immunotherapy in multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
- Department of Cell Biology, School of Basic Medicine, Harbin Medical University, Harbin 150081, China.
ORCID-Profile: Wei Wang
Förderung
- Natural Science Foundation of Hei-longjiang Province
- a transvers research project funded by the Bei jing Huikang Charity Foundation
- Beijing Huikang Charity Foundation
- Beijing Health Promotion Association
Zitieren
APA
Leng, S., Tian, Y., Liu, Y., Zhao, W., & Wang, W. (2026). Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma. International Journal of Molecular Sciences, 27(15), 6602. https://doi.org/10.3390/ijms27156602
Vancouver
Leng S, Tian Y, Liu Y, Zhao W, Wang W. Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma. International Journal of Molecular Sciences. 2026;27(15):6602. doi:10.3390/ijms27156602
BibTeX
@article{Leng2026,
author = {Leng, Songze and Tian, Yaoyao and Liu, Yao and Zhao, Weiwei and Wang, Wei},
title = {Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6602},
doi = {10.3390/ijms27156602}
}
EUVIMED